糖皮质激素联合非生物型人工肝治疗重症药物性肝损伤疗效及安全性

摘要/Abstract

摘要： 目的评估糖皮质激素联合非生物型人工肝治疗重症药物性肝损伤的效果及安全性。方法对激素联合人工肝治疗的96例重症药物性肝损伤患者进行回顾性分析,记录其治疗过程及血常规、肝功能等指标,观察其有效率及并发症。结果 96例重症药物性肝损伤患者治疗有效者84例,无效12例,治疗后RBC(4.22±0.70)×10⁹/L、Hb(127.88±22.99) g/L较前升高,差异有统计学意义(P<0.05);ALT(145.48±158.94) U/L、AST(98.06±69.26) U/L、TBil(165.10±124.21) μmol/L、DBil(130.66±89.46) μmol/L、IBil(35.43±37.48) μmol/L、Alb(41.12±30.93) g/L、ALP(178.64±119.65) U/L较治疗前有明显改善,差异均有统计学意义(P<0.05);BUN(5.61±2.59) mmol/L、Cre(61.00±14.36) μmol/L较前升高,差异有统计学意义(P<0.05),血凝各指标较前无明显变化,差异无统计学意义(P>0.05)。结论激素联合人工肝治疗重症药物性肝损伤患者,疗效肯定,安全性较好,可延缓病情进展,降低肝衰竭发生率。

关键词: 药物性肝损伤, 重症, 激素, 人工肝, 疗效, 安全性

Abstract: Objective To evaluate efficacy and safety of glucocorticoid (GC) with non-bioartificial liver support system (NBLS) in the treatment of severe drug-induced liver injury (DILI). Methods In the retrospective study, 96 cases with severe DILI who had underwent the treatment of GC combined NBLS in our hospital from January 2008 to December 2015 were enrolled. Treatment, blood routine, liver functions, and so on, were recorded. The efficacy and complications of GC combined with NBLS in treating severe DILI were observed.Results Treatment of GC combined with NBLS was effective in 84 cases (87.5%). Levels of red blood cell (RBC) (4.22±0.70)×10⁹/L and hemoglobin (Hb) (127.88±22.99) g/L were significantly higher at baseline than those after treatment (P<0.05). Levels of alanine aminotransferase (ALT) (145.48±158.94) U/L, aspartate amino transferase (AST)(98.06±69.26) U/L, total bilirubin (TBil) (165.10±124.21) μmol/L bilirubin tra, direct bilirubin (DBil) (130.66±89.46) μmol/L, indirect bilirubin (IBil) (35.43±37.48) μmol/L, albumin (Alb) (41.12±30.93) g/L and alkaline phosphatase (ALP) (178.64±119.65) U/L were significantly improved compared to those before treatment (P<0.05). However, levels of blood urea nitrogen (BUN) (5.61±2.59) mmol/L and cre-recombinase (Cre) (61.00±14.36) μmol/L in renal function were significantly higher after treatment (P<0.05). No significant difference was observed in the level of prothrombin time (PT) and plasma thromboplastin antecedent (PTA) (P>0.05). Conclusion The treatment of GC with NBLS showed satisfactory effectiveness and safety for severe DILI, which could ameliorate the disease progression, reduce total incidence of liver failure and improve the prognosis.

Key words: Drug-induced liver injury, Severe, Glucocorticoid non-bioartificial liver support system, Efficacy, Safety

贺娜,郑洋洋,齐云飞,朱绍华,张静,李娜,尹芳,周新民. 糖皮质激素联合非生物型人工肝治疗重症药物性肝损伤疗效及安全性[J]. 肝脏, 2017, 22(6): 509-512.

HE Na,ZHENG Yang-yang,QI Yun-fei, ZHU Shao-hua,ZHANG Jing,LI Na,YIN Fang,ZHOU Xin-min. Efficacy and safety of glucocorticoid with non-bioartificial liver support system in the treatment of severe drug-induced liver injury[J]. Chinese Hepatolgy, 2017, 22(6): 509-512.

参考文献 17

[1]	Ju C,Reilly T.Role of immune reactions in drug-induced liver injury (DILI).Drug Metab Rev,2012,44:107-115.
[2]	Czaja AJ. Drug-induced autoimmune-like hepatitis.Dig DisSci,2011,56: 958-976.
[3]	Maria VA, Victorino RM. Development and validation of a clinicai scale for the diagnosis of drug-induced hepatitis. Hepatology, 1997, 26:664-669.
[4]	Danan G,Benichou C.Causality assessment of adverse reactions to drugs I.A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries.J Clin Epidemiol,1993,46:1323-1330.
[5]	Hunt CM,Papay JI,Edwards RI,et al.Monitoring liver safety in drug development:the GSK experience.Regul Toxicol Pharmaeol,2007,49:90-100.
[6]	Chalasani NP,Hayashi PH,Bonkovsky HL,et al.ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.Am J Gastroenterol,2014,109:950-966.
[7]	Hayashi PH,Fontana RJ.Clinical features,diagnosis,and natural history of drug－induced liver injury.Semin Liver Dis,2014,34:134-144.
[8]	中华医学会传染病与寄生虫病学分会人工肝学组.人工肝支持系统的适应证、禁忌证和疗效判断. 中华肝脏病杂志, 2002,10:405.
[9]	Miguel A,Azevedo LF,Araujo M,et al.Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis.Pharmacoepidemiol Drug Saf,2012,21: 1139-1154.
[10]	张绪清, 聂青和.糖皮质激素在治疗重型肝炎中的应用及评价. 实用肝脏病杂志, 2004,7: 70-72.
[11]	汪萌,聂青和. 糖皮质激素治疗重型肝炎肝衰竭患者的疗效及并发症临床荟萃分析. 临床肝胆病杂志, 2012,28:764-770.
[12]	Hoeper MM,Olsson KM,Schneider A,et al.Severe hepatitis associated with sitaxentan and response toglucocorticoid therapy.Eur Respir J,2009,33: 1518-1519.
[13]	徐张巍,许建明.糖皮质激素治疗药物性肝损伤重症倾向的临床研究.安徽医科大学学报,2012,47: 562-564.
[14]	Nakatomi K,Nakamura Y,Tetsuya I,et al.Treatment with gefitinib after erlotinib-induced liver injury: a case report.J Med Case Rep,2011,5: 593.
[15]	Reuben A,Koch DG,Lee WM.Drug-induced acute liver failure: results of a U.S.multicenter,prospective study.Hepatology,2010,52: 2065-2076.
[16]	陈成伟.药物性肝病的发病机制及诊治. 肝脏,2007,12: 297-302.
[17]	European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of cholestatic liver diseases.J Hepatol,2009,51: 237-267.